CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A recommended scale for cognitive screening in clinical trials of Parkinson's disease
Authors
Aarsland
Aarsland
+31 more
Athey
Carod-Artal
Crum
Di Virgilio
Dubois
Emre
Ferris
Folstein
Gill
Hely
Hobson
Hoops
Kalbe
Kulisevsky
Llebaria
Mahieux
Marinus
Mattis
Muller
Nasreddine
Nazem
Pagonabarraga
Pagonabarraga
Reyes
Riedel
Stern
Tombaugh
Uc
Verbaan
Wind
Zadikoff
Publication date
1 January 2010
Publisher
'Wiley'
Doi
Cite
View
on
PubMed
Abstract
Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder SocietyPeer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/78295/1/23362_ftp.pd
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Deep Blue Documents at the University of Michigan
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:deepblue.lib.umich.edu:202...
Last time updated on 25/05/2012
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1002%2Fmds.23362
Last time updated on 01/04/2019
Sustaining member
University of Miami: Scholarship Miami
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:alma.01UOML_INST:113798910...
Last time updated on 16/01/2024
Carolina Digital Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
cdr.lib.unc.edu:5m60r096n
Last time updated on 24/11/2020
Barrow - St. Joseph's Scholarly Commons
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:scholar.barrowneuro.org:ne...
Last time updated on 23/07/2022